subject inclusion question in replicate design for ANVISA [RSABE / ABEL]

posted by Shuanghe  – Spain, 2019-09-05 16:38 (1858 d 20:17 ago) – Posting: # 20544
Views: 3,031

Hi Helmut,

❝ ❝ […] the client's statistical consultant commented that only subjects who complete all 4 period (2T+2R) should be included, otherwise, they should be excluded even if they completed 3 period.


❝ IMHO, this doesn’t make sense. See the example in the vignette of replicateBE.


Thanks. That's my thought too so I insisted that the statistical section should be kept unchanged. Hopefully ANVISA will issue their own guideline soon...

All the best,
Shuanghe

Complete thread:

UA Flag
Activity
 Admin contact
23,247 posts in 4,885 threads, 1,652 registered users;
69 visitors (0 registered, 69 guests [including 9 identified bots]).
Forum time: 12:56 CEST (Europe/Vienna)

The real struggle is not between the right and the left
but between the party of the thoughtful
and the party of the jerks.    Jimmy Wales

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5